Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols

Leukemia

Volumn 17, Issue 6, 2003, Pages 1085-1090

  Mandelli, F ^a   Latagliata, R ^a   Avvisati, G ^b   Fazi, P ^a   Rodeghiero, F ^c   Leoni, F ^d   Gobbi, M ^e   Nobile, F ^m   Gallo, E ^f   Fanin, R ^g   Amadori, S ^h   Vignetti, M ^a   Fioritoni, G ^m   Ferrera, F ⁱ   Peta, A ^j   Giustolisi, R ^k   Broccia, G ^m   Petti, M C ^l   Lo Coco, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c San Bartolo Hospital   (Italy)

^d Policlinico Careggi   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL OF UDINE   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ CARDARELLI HOSPITAL   (Italy)

^j PUGLIESE CIACCIO HOSPITAL   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^m NONE

more..

Author keywords

Acute promyelocytic leukemia; AML of the elderly; ATRA

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; RETINOIC ACID; STEROID; TIOGUANINE;

AGE; AGED; ARTICLE; BRAIN PSEUDOTUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; FREQUENCY ANALYSIS; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RETINOIC ACID SYNDROME; SURVIVAL TIME;

EID: 0038378897     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402932     Document Type: Article

References (29)

1. Warrell Jr RP. Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996; 47: 555-565.
2. Frankel SR, Powell BL. Current approaches to acute promyelocytic leukemia. In: Tallman MS, Gordon LI (eds). Diagnostic and Therapeutic Advances in Hematologic Malignancies. Boston: Kluwer Academic Publishers, 1999, pp 125-153.
3. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001; 20: 7140-7145.
4. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
5. Avvisati C, Mele A, Stazi MA, Vegna ML, Pasquini P, Mandelli F. Epidemiology of acute promyelocytic leukemia in Italy. Ann Oncol 1991; 2: 405-408.
6. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483-490.
7. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014-1021.
8. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
9. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell Jr RP. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997; 40(Suppl): S25-S29.
10. Asou N, Adachi K, Tamura J, Kanamaru A, Kagayama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16: 78-85.
11. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131-4143.
12. Sanz MA, Martin G, Rayon C, Esteve J, Gonzales M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
13. Wang Z, Sun G, Shen Z, Chen S, Chen Z. Differentiation therapy for acute promyeloctyc leukemia with all-trans retinoid acid: 10-year experience of its application. Chin Med J 1999; 112: 963-967.
14. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
15. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362-1370.
16. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol 1997; 8: 1273-1275.
17. Latagliata R, Petti MC, Mandelli F. Acute myeloid leukemia in the elderly: 'per aspera ad astra'? Leukamia Res 1999; 84: 814-819.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Calton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med 1985; 103: 620-625.
19. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
20. Chomczynsky P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Ann Biochem 1987; 162: 156-159.
21. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F et al. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214-1216.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
24. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
25. Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martinelli G et al. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study. Leukemia 2001; 15: 1696-700.
26. Douer D, Estey E, Santillana S, Bennet JM, Lopez-Bernstein G, Boehm K et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73-80.
27. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
28. Dombret H, Fenaux P, Soignet SL, Tallman MS. Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39(Suppl 1): 8-13.
29. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822-824.